The cost-effectiveness of iruplinalkib versus alectinib in anaplastic lymphoma kinase-positive crizotinib-resistant advanced non-small-cell lung cancer patients in China
Article in Frontiers in Public Health (April 2024)
The most recent citing publications are shown below. View all 9 publications that cite this research output on Dimensions.
Article in Frontiers in Public Health (April 2024)
Article in JCO Global Oncology (February 2024)
Article in Frontiers in Public Health (February 2024)